銅 Copper × 心血管疾病
結論：證據支持
現有人體證據幾乎全為觀察性研究（cohort/case-control/cross-sectional），雖一致顯示血清銅升高與 CV 死亡率/MI/中風風險增加（Muñoz-Bravo 2023 SR/MA n=41,322, pOR 1.
C 🟠 C 薄弱證據 已發布 ✨ low — community discussion mostly non-commercial
現有人體證據幾乎全為觀察性研究（cohort/case-control/cross-sectional），雖一致顯示血清銅升高與 CV 死亡率/MI/中風風險增加（Muñoz-Bravo 2023 SR/MA n=41,322, pOR 1.60 [1.39-1.86] for CV mortality；KIHD 27 年前瞻 HR 1.32），但因果關係未確立——升高的血清銅高度可能是發炎/急性期反應的標記（ceruloplasmin 為 acute-phase reactant；調整 hsCRP 後過量風險減 33%）。
無任何 RCT 顯示補充銅可降低 CVD 事件；AHA/ACC/NLA/ESC 全數沉默無背書；NIH ODS 明確不建議補銅以預防 CVD；FDA/EFSA/NHS/TFDA 皆僅承認其為必需營養素（RDA 900 µg、UL 10 mg）而無任何疾病療效宣稱；Mayo/Cleveland/Harvard 三大病人衛教來源亦無支持。
U 形「低端 harm」僅來自罕病基因（Menkes/ATP7A）與動物模型，不能外推到一般成人補充情境。
因此「補銅作為 CVD 介入」屬薄弱證據（C tier）—機轉合理但無人體 RCT 支持，且觀察證據實際指向相反方向（高銅 = 較高風險）。
⚖️
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查原始分數 0.48
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
C · 已發布
信心度
71%
證據方向大致一致
證據層級
E2
多篇高品質統合分析（≥2 篇一致）
▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.477
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (3 篇 > 0 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
Serum copper levels and risk of major adverse cardiovascular events: a systematic review and meta-analysis
結論：Highest vs lowest serum copper associated with increased risk of total stroke (pOR 1.49, 95% CI 1.22-1.82), myocardial infarction (pOR 1.31, 95% CI 1.17-1.46), and cardiovascular mortality (pOR 1.60, 95% CI 1.39-1.86). Subgroup hybrid-design analyses showed even stronger CV mortality association (pOR 3.42). No dose-response/U-shape modelled explicitly; all participants typically within reference range.
前往 PubMed
Association of serum copper (Cu) with cardiovascular mortality and all-cause mortality in a general population: a prospective cohort study
結論：T3 vs T1 serum Cu: CV mortality HR 7.06 (95% CI 1.85-26.96); all-cause mortality HR 2.84 (95% CI 1.66-4.87). Restricted cubic spline showed near-linear positive association (non-linearity p=0.48 for CVD, 0.62 for all-cause) — i.e. monotonic increase rather than clear U-shape in this cohort. Three-cohort pooled estimate (n=13,189) confirmed HR 2.08 (1.63-2.65) for CVD and HR 1.89 (1.58-2.25) for all-cause mortality.
前往 PubMed
Circulating Serum Copper Is Associated with Atherosclerotic Cardiovascular Disease, but Not Venous Thromboembolism: A Prospective Cohort Study
結論：CHD top vs bottom tertile HR 1.32 (95% CI 1.10-1.59) after multivariable adjustment — confirms atherosclerotic-specific association. VTE: HR 1.02 (0.88-1.20) per 1 SD; HR 0.99 (0.82-1.19) multivariable-adjusted; no association. Dissociation between atherosclerotic CVD and venous thrombosis supports a mechanism involving oxidative stress/vascular inflammation rather than coagulation.
前往 PubMed
Association between serum copper levels and risk of cardiovascular disease: A nested case-control study in the PREDIMED trial
結論：Highest vs lowest Cu quartile in MEN: OR 2.36 (95% CI 1.07-5.20), p-trend=0.02. In WOMEN: OR 0.43 (95% CI 0.11-1.70), p-trend=0.165 — no association. Mean S-Cu male cases 1014.1 vs controls 959.3 µg/L (p=0.004). Strong sex-effect modification.
前往 PubMed
Association between serum copper and heart failure: a meta-analysis
結論：HF patients had significantly higher serum copper than controls: overall SMD 0.982 (95% CI 0.679-1.285). Effect significant in Asia (SMD 0.948, 0.569-1.327) and Europe (SMD 1.275, 0.633-1.917) but not America (SMD 0.637, -0.109-1.383). Both ischemic cardiomyopathy (SMD 1.171, 0.717-1.624) and idiopathic dilated cardiomyopathy (SMD 0.569, 0.097-1.042) showed elevated Cu. Cross-sectional design cannot establish causality — Cu elevation may reflect inflammation/acute phase response in HF.
前往 PubMed
Ceruloplasmin and Coronary Heart Disease - A Systematic Review
結論：Most (majority of 18) eligible studies support a direct, graded relationship between elevated ceruloplasmin and incident CHD/MI/CV mortality. Helsinki Heart Study showed graded risk increase across ceruloplasmin levels; elderly prospective cohort showed adjustment for hsCRP and leukocyte count reduced excess risk by ~33% — suggesting both inflammation-mediated and inflammation-independent components. Authors call for trials to determine causal vs marker role. No quantitative pooled effect size reported.
前往 PubMed
Copper Transporter ATP7A (Copper-Transporting P-Type ATPase/Menkes ATPase) Limits Vascular Inflammation and Aortic Aneurysm Development: Role of MicroRNA-125b
結論：ATP7A overexpression prevented Ang II-induced AAA; ATP7A dysfunction promoted AAA with copper accumulation, increased macrophage recruitment, elevated MMP-2/9, elastin fragmentation, VSMC apoptosis. Mechanism mediated via miR-125b downregulation → derepressed proinflammatory cytokines; anti-miR-125b reversed phenotype. Establishes ATP7A as causal modulator of vascular Cu handling and inflammatory vascular disease — therapeutic target.
前往 PubMed
Increased frequency of congenital heart defects in Menkes disease
結論：4 of 95 patients (4.2%) had major congenital heart defects vs ~1% general-population prevalence — ~4-fold excess. Combined with established Menkes vascular tortuosity (arising from lysyl-oxidase, a Cu-dependent enzyme, deficiency), provides human-genetic evidence that severe Cu deficiency causes structural cardiovascular disease at the low end of the U.
前往 PubMed
L4a US FDA
支持
Copper ... 0.9 mg 來源↗
L4b EU EFSA
支持
contributes to maintenance of normal connective tissues; contributes to normal functioning of the nervous system; contributes to normal cognitive function 來源↗
L4c UK NHS
謹慎
You should be able to get all the copper you need by eating a varied and balanced diet. 來源↗
L4d TW TFDA / 衛福部
支持
形態屬膠囊狀、錠狀且標示有每日食用限量之食品，在每日食用量中，其銅含量不得高於8毫克。限於補充食品中不足之營養素時使用。 來源↗
L4e WHO
中性
A health-based guideline value of 2 mg/litre has been derived for copper in drinking-water... Copper is both an essential nutrient and a drinking-water contaminant. 來源↗
L5a NIH Office of Dietary Supplements
支持
Copper, an essential mineral, is naturally present in some foods and is available as a dietary supplement. It is a cofactor for several enzymes (known as 'cuproenzymes') involved in energy production, iron metabolism, neuropeptide activation, connective tissue synthesis, and neurotransmitter synthesis. 來源↗
L5b Mayo Clinic
中性
— 本適應症無對應資料
L5c Cleveland Clinic
謹慎
L5d Harvard Health
中性
— 本適應症無對應資料
L5e Specialty Society (condition-mapped)
中性
— 本適應症無對應資料
PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 低度
低中高
📍立場總覽
PTT（regimen 養生板）、Dcard、Mobile01 幾乎沒有把「銅」當作心血管保健補充品的在地討論。銅僅在「抗氧化微量元素／SOD」「硒鋅銅鐵錳」等泛談文中被順帶提及，並非社群主動推薦或實測的護心成分。台灣社群護心話題集中在魚油、紅麴、納豆、薑黃、Q10、精胺酸，無人特意補銅，亦無相關品牌、劑量或副作用回饋。屬冷門題目，無真實社群聲量。
💬社群實感
無共識（社群幾乎無人將銅作為心血管保健補充品討論）
- 生活型態優化（健康飲食、身體活動、戒菸）
- 史他汀類藥物（適應症族群）
- 戒菸（行為介入合併藥物）
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-cardiovascular-disease-INT-copper-001/",
"datePublished": "2026-06-01",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "銅能改善心血管疾病",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 2,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🟠 C 薄弱證據"
}
}